Literature DB >> 2954873

Multiple low-dose streptozotocin-induced diabetes in the mouse: further evidence for involvement of an anti-B cell cytotoxic cellular auto-immune response.

R C McEvoy, N M Thomas, C Hellerström, F Ginsberg-Fellner, T M Moran.   

Abstract

Anti-B cell auto-immunity may play a role in the pathogenesis of diabetes in mice resulting from multiple subdiabetogenic doses of the pancreatic B cell toxin, streptozotocin. In the present study we have investigated the cytotoxic anti-B cell response in these mice. A major role for B lymphocytes, macrophages, or their products in the cytotoxic response originally detected in vitro was eliminated by passing splenocytes from the mice treated with multiple subdiabetogenic doses of streptozotocin over a nylon wool column. The removal of the adherent cells enhanced the cytotoxicity against a rat insulinoma cell line in vitro by that expected due to enrichment of T-lymphocytes by approximately two-fold. The induction of diabetes after multiple subdiabetogenic doses of streptozotocin is strain dependent. Mice of five strains were immunized with rat insulinoma cells, but only splenocytes from the two strains susceptible to multiple subdiabetogenic doses of streptozotocin demonstrated a significant cytotoxic response against the rat insulinoma cells in vitro. Mice pre-immunized with either the rat insulinoma cells or with syngeneic islets labelled in vitro with the hapten trinitrophenol developed hyperglycaemia more rapidly than control mice after multiple subdiabetogenic doses of streptozotocin. In the latter experiment the control mice immunized with complete Freund's adjuvant alone also became hyperglycaemic after a modified multiple subdiabetogenic dose of streptozotocin that did not cause diabetes in non-immunized mice. In mice pre-treated with either adjuvant or cyclophosphamide and then given a modified multiple subdiabetogenic dose of streptozotocin (35 mg/kg X 5 rather than 40 mg/kg) the degree of hyperglycaemia was reduced and there was no protective effect of cyclophosphamide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954873     DOI: 10.1007/bf00270421

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  44 in total

1.  On the enzymatic determination of blood glucose.

Authors:  E RAABO; T C TERKILDSEN
Journal:  Scand J Clin Lab Invest       Date:  1960       Impact factor: 1.713

2.  Streptozotocin: depression of mouse liver pyridine nucleotides.

Authors:  P S Schein; S Loftus
Journal:  Cancer Res       Date:  1968-08       Impact factor: 12.701

3.  MHC class II antigen expression on the various cells of normal and activated isolated pancreatic islets.

Authors:  K Ulrichs; W Müller-Ruchholtz
Journal:  Diagn Immunol       Date:  1985

4.  Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans.

Authors:  T Mandrup-Poulsen; K Bendtzen; J Nerup; C A Dinarello; M Svenson; J H Nielsen
Journal:  Diabetologia       Date:  1986-01       Impact factor: 10.122

5.  The effect of radioimmunosuppression on the development of low-dose streptozotocin diabetes.

Authors:  H J Hahn; K Barnstorf; R Nadrowitz; W Besch; W Schmidt
Journal:  Acta Biol Med Ger       Date:  1982

6.  Protection against streptozotocin-induced diabetes by superoxide dismutase.

Authors:  M J Robbins; R A Sharp; A E Slonim; I M Burr
Journal:  Diabetologia       Date:  1980-01       Impact factor: 10.122

7.  Genetic control of pathogenesis of diabetes in C3H mice. Influence of the major histocompatibility complex.

Authors:  E H Leiter
Journal:  Diabetes       Date:  1984-11       Impact factor: 9.461

8.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus.

Authors:  A A Like; A A Rossini
Journal:  Science       Date:  1976-07-30       Impact factor: 47.728

9.  Genetic control of low-dose streptozotocin-induced autoimmune diabetes in mice.

Authors:  U Kiesel; F W Falkenberg; H Kolb
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

10.  Interferon-gamma enhances the expression of the major histocompatibility class I antigens on mouse pancreatic beta cells.

Authors:  I L Campbell; G H Wong; J W Schrader; L C Harrison
Journal:  Diabetes       Date:  1985-11       Impact factor: 9.461

View more
  6 in total

1.  Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice.

Authors:  G Kantwerk-Funke; V Burkart; H Kolb
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

2.  Heparin attenuates low-dose streptozotocin-induced immune diabetes in mice and inhibits the beta-cell binding of T-splenocytes in vitro.

Authors:  P Saï; S Pogu; M Ouary
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

3.  B cell-adherent splenocytes precede the onset of diabetes in low-dose streptozotocin-treated mice.

Authors:  B Feve; J P Segain; B Charbonnel; P Sai
Journal:  Diabetologia       Date:  1990-01       Impact factor: 10.122

4.  Transfected rat islet tumour cells express mouse major histocompatibility complex class I antigens functionally. Applicable as "pseudo-syngeneic" targets in the multiple low-dose streptozotocin diabetes model.

Authors:  P Serup; J Schøller
Journal:  Diabetologia       Date:  1989-07       Impact factor: 10.122

5.  Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes.

Authors:  Taylor Fuselier; Paula Mota de Sa; M M Fahd Qadir; Beibei Xu; Camille Allard; Mathew M Meyers; Joseph P Tiano; Bin S Yang; Vasily Gelfanov; Sarah H Lindsey; Richard D Dimarchi; Franck Mauvais-Jarvis
Journal:  Cell Rep Med       Date:  2022-04-07

6.  Streptozotocin-Induced Diabetes in a Mouse Model (BALB/c) Is Not an Effective Model for Research on Transplantation Procedures in the Treatment of Type 1 Diabetes.

Authors:  Michal Wszola; Marta Klak; Anna Kosowska; Grzegorz Tymicki; Andrzej Berman; Anna Adamiok-Ostrowska; Joanna Olkowska-Truchanowicz; Izabela Uhrynowska-Tyszkiewicz; Artur Kaminski
Journal:  Biomedicines       Date:  2021-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.